Sunday, August 09, 2009

The Competition Commission: Separation of Power troubles again?


Earlier on this blog, a series of posts had covered some of the IP-related issues in the Competition Act, 2002. Now, with several of the Acts provisions in force, I intend to look at some aspects of the Act in detail. Particularly, I intend to focus on the following areas; though with the help of our readers’ comments, I hope that the discussion shall cover other related areas too:


1. The Competition Commission

2. Exclusive agreements: When are they anti-competitive?

3. Can enforcing IP be an abuse of dominant position?

4. Section 3(5): Exceptions for IP

The Competition Commission


In recent days, the idea of executive authorities performing quasi-judicial functions has been strongly questioned. On Indian Corporate Law, I had written about a Constitution Bench hearing into the constitutionality of the National Company Law Tribunal. The law on the point will hopefully be clarified by the decision. (Of course, there is a seven-judge decision on the point, Chandra Kumar; yet, the position remains unclear).


How does the Competition Commission go about balancing the task of not violating separation of power principles with the need to have technical (and not just legal) experts? The Supreme Court in Brahm Dutt was called on to examine the issue of the constitutionality of the Commission. However, in view of the proposed amendments to the Act, the Supreme Court did not adjudicate the issue on merits. The writ petition was “disposed of leaving open all the relevant questions…” Prashant has discussed separation of power issues with respect to the Patent Office in his post here. Several of the concerns he raises may apply to the Competition Act also.

The current version of the Act is accessible here. The Composition of the Commission is discussed in Section 8. The Chairperson and Members must be persons qualified, among other things, in areas “including competition law and policy.” Further, the term of office of the Chairperson and other members is 5 years, after which they are (subject to a maximum age-cap of 65) eligible for re-appointment.


The Appellate Tribunal also has the same features. One difference is that a Judge heads the Appellate Tribunal; but the other member need not be a qualified judge. In fact, Section 53D(2) states that a member of the Appellate Tribunal should have experience in competition law, economics … or in any other matter which in the opinion of the Central Government, may be useful to the Appellate Tribunal! The 5-year term, with eligibility for re-appointment, is present here as well.


I have serious doubts over whether being qualified in areas “including competition law” is sufficient to discharge judicial functions. Furthermore, is it proper for a member of a (quasi) judicial body to be given a fixed term in office, and then being eligible for re-appointment? Would this not result in possible executive influence, considering that there is no security of tenure as such? Should not the qualifications and conditions of service be comparable with those of, say, a High Court Judge?


It might well be argued that the Commission is only playing a supplemental role to the judiciary; and not a substituting role. For instance, it can be argued the Act does not bar recourse to the writ jurisdiction of the High Court under Article 226 of the Constitution. This is true, but perhaps only in theory. For, the Act gives a statutory right to appeal to the Supreme Court (Section 53T). No High Court will entertain a 226 petition when there is a statutory Supreme Court appeal. In that scenario, is not the jurisdiction of High Courts under Article 226 effectively being taken away? If it is being taken away, should that jurisdiction not vest in a body composed similar to the High Courts? Will the principle of separation of powers be respected, if we say that writ petitions under Article 226 may be heard by any person who the government thinks is qualified, just because there is an appeal before the Supreme Court provided for?


The Commission itself may well need to have several technical experts. But, the constitution of the Appellate Tribunal at the very least appears to be open to a serious separation-of-powers challenge. What do our readers think?

Ramkumar vs Cell Importers: India's Biggest IP Case Yet?

The Madras High Court recently dismissed a writ petition filed by Ramkumar against the orders of the Customs Commissioners (in Chennai, Mumbai and Delhi). As noted in previous posts, these detailed orders by the commissioners held in favour of the cell phone importers (such as Samsung, Hansum and Spice Mobile), noting that Ramkumar's patent did not cover "dual SIM" phones in their entirety, but only those dual SIM phones that permitted simultaneous communication as well.

Ramkumar proceeded to challenge these orders before the High Court in a writ petition. He also managed to obtain an ex parte stay of the Customs orders from the High Court. However, after a full hearing of both the parties, the court decided to hold in favour of the importers. In pertinent part, it held that the proper venue for redressal in this case was the Customs Appellate Tribunal, an authority envisaged as the appellate authority under the Customs Act. Since this efficacious alternative remedy was available, the petitioner cannot agitate the matter before the High Court, without first exhausting such alternative remedy.

Ramkumar also argued that the customs authorities had denied him the right to a fair hearing and thereby violated cardinal principles of natural justice. However, the court found that Ramkumar had been offered an opportunity of being heard by all the commissioners. He chose not to appear...and therefore it was incorrect of him to now allege that he was given no opportunity of being heard.

The Ramkumar litigation which has now spanned diverse fora including customs authorities, the Madras High Court, the Gurgaon district court, the Punjab and Haryana High Court, the Central Excise Authorities, the IPAB and the Delhi High Court is slated to become the biggest IP litigation that India has witnessed so far. Or at least the most "proliferative".

Even assuming Ramkumar loses, he can take some pride in the fact that he spawned a landmark case and contributed in some way to India's fledgling patent jurisprudence. Of course, the small time importers who ended up paying him huge sums without questioning his preposterous patent claims are not likely to view him in such a favourable light. If they chose to take him to court and recover moneys they paid him under a mistaken belief, we could have yet another stream of IP "compensatory" jurisprudence emerging, where makers of blatantly false IP claims are penalised by the law and forced to make good the losses.

Saturday, August 08, 2009

SpicyIP Tidbits: E-book on Evolving Contours of GIs

There is growing awareness in India of geographical indications as a separate form of intellectual property, even if there is constant mis-reporting of GIs as patents, trademarks, etc., which we will continue to berate here until there is actual clarity on the differences!

Meanwhile, to help understand the international policy background in which GIs have emerged, and its application in various parts of the world, the Institute of Intellectual Property Studies (IIPS) and the MVIRDC World Trade Centre have brought out a new publication on “Geographical Indications: Its Evolving Contours” (download here) as a monograph in the WTO Study Series.

The e-book was written by Dr Prabuddha Ganguli, a highly respected IP expert, who has held key advisory positions in India and abroad, besides having a wealth of industry, IP and policy experience.

As the foreword to the paper informs us: A number of International Conventions, including The Paris Convention, The Madrid Agreement, The Lisbon Agreement and TRIPs have addressed the issue of GIs. This study presents an overview of the interpretations and evolution of the concept of GIs in the context of the various International Conventions. It also critically examines the system and practice of GI protection in various countries, citing interesting cases.

The GI approaches in the Indian system is analyzed with reference to case studies in several Indian products, including tea, textiles, carpets, handicrafts, horticultural products, soap and essential oil, paintings, etc.
The study also presents highlights of important GI disputes in the international arena for better appreciation of the specific interests of the concerned parties and the economic impact in the wake of such disputes. The study also discusses the present debate at the WTO in the context of extending higher levels of protection beyond wines and spirits.


Just to jog your memory, the Institute of Intellectual Property Studies (IIPS) is one of the most reputed and perhaps oldest IP training institutes from India, which has recently begun its latest edition of programs in IP, which was blogged about here.

IIT alums lead the way in incubating ideas

A new project of the PanIIT Alumni India to promote innovation in India may be just the right push needed to bring the achievements of budding inventors and innovators to fruition.


EFY Times reports that the
India Technology Centre (ITC) will be functioning under the aegis of PanIIT Alumni India (PIAI), with its primary objectives as follows:
  • To promote and foster a culture of innovation and invention in India.
  • To provided support and guidance to inventors, and help them to develop, register and license their patents.
  • To be a reliable source of information on matters of technology and policy to the public and society.
The IITs are leading the way in innovation in India already, with incubation centres and mentors on offer in almost all the IITs. I am not sure of how the ITC is connected with existing incubators, but I'm sure there will be attempts to coordinate and support the activities that are already ongoing.

This initiative is particularly of interest to SpicyIP, which has been, almost annoyingly, harping on the need to have an "innovation culture" in this country, and how policymakers, academic and research institutions, and corporate entities can help create that.

There's a neat little concept note on the ITC that you can download and read here, which intends to broaden the institutional set-up already available, through four components which I summarise below:

1. DATA & INFORMATION CENTRE (DIC): A one-stop shop for information and due diligence on inventions, including:
  • Has the invention been patented already?
  • Is it worth patenting?
  • What is the potential value of such an invention?
  • What is the time and cost involved in applying for and being granted a patent?
  • Venture capital resources to pursue the invention development
  • Potential licensees for the end-product
The DIC will have access to international technology and research databases through high-speed internet links, and also provide the public on-line access to its own information databases. It will have free and charged access options for different levels of access.

2. INNOVATION CENTRE (IC): This will be an organisation to create opportunities for the interaction of Indian students, researchers and technologists with global thought leaders and innovators. This will also house the Hall of Invention, a permanent exposition focusing on the inventors and inventions that have impacted human development, and where technology may take us in the future.

3. RESEARCH & ANALYSIS INSTITUTE (RAI): The “Think Tank” in the project which will offer information and advice on emerging trends and technologies, as well as undertake commissioned studies.

4. INCUBATION CENTRE (FIC): A centre where anyone with an idea but lacking resources and facilities can build their prototypes. It will provide Technical information and advice, Entrepreneurship development, Mentorship, Facilities for for development of prototypes and working models. It will also aid the development of solutions for India specific problems.

The India Technology Center is an idea still in the concept stage, and we shall wait to see how things pan out. Regardless, it is a much-needed initiative, which will surely have potential entrepreneurs lining up waiting to cash in on their ideas!

Rigging Data: IPR's and the IMPACT of Counterfeits


There's no dearth of counterfeiting and piracy data. And the figures escalate year after year. Naturally these figures are followed up with clarion calls to have more aggressive IPR enforcement. And often times, these heavy duty figures (which span a variety of IP industries such as pharmaceuticals, software, music and movies) are followed up by figures on loss of jobs, employment etc as a consequence of piracy and counterfeiting. And more recently, these figures have also been linked up to terrorism!

Think of the controversial WHO figures on spurious drugs in India. A recent article throws light on this unsavoury episode:

"In 2003, representatives of the Confederation of Indian Industry (CII) told a committee of experts on drugs regulation that the World Health Organisation (WHO) had estimated that “35 percent of fake drugs produced in the world come from India, which has a INR 4,000 crore (USD 809.7 million) spurious-drug market. About 20 percent of medicines in the country are fake or sub-standard. Of these, 60 percent do not contain any active ingredient, 19 percent contain wrong ingredients, and 16 percent have harmful and inappropriate ingredients.” It all sounds pretty bad: if true, people in India are as likely to be suffering from partially and untreated illnesses or adverse reactions, as much as from the conditions themselves.

However, these claims are largely unsupported by evidence. When the head of the committee, Dr R A Mashelkar, challenged the CII to supply its sources, the latter failed to deliver anything to support its claims. The WHO also denied ever having produced a study with the results attributed to it – in a report from 2006, it had merely repeated the claims of the companies themselves: “Indian pharmaceutical companies have suggested that in India’s major cities, one in five strips of medicines sold is a fake."

Naturally some of these "spurious drug" figures might have motivated global anti-counterfeiting initiatives that are now doing the rounds: from IMPACT to ACTA to SECURE. Apart from questioning the false IP-public safety linkages that some of these initiatives are premised on, one must also carefully scrutinise the rather generous counterfeiting figures floating around.

A recent presentation notes that falsification of seizure figures is endemic in the anti-counterfeiting industry. In particular, it highlights two problematic practices:

i) Trap Orders: Where [anti counterfeiting] service providers place an order of counterfeit products, then seize it (this might include teaching an “innocent”manufacturer how to make counterfeits)

ii) Fake raid actions: Where there is no raid action at all. But seizure lists are freely invented and old Photographs of previous cases are “recycled”to make up a nice report.

Let me however clarify that I do not take issue with the collection and dissemination of data to provide for more optimal IP policy. Indeed as we've noted several times on this blog, we need to move away from "Faith Based" IP to "Fact Based" IP. And one way to do so is by collecting hard, factual data.

However, rigging data and deploying other fraudulent means is another issue altogether. And enthusiasts of IP enforcement should appreciate that rigging data to make a better case for a more aggressive IPR enforcement will engender more harm than good and make them lose credibility in the long run.

Friday, August 07, 2009

Guest Post: Patents Patents Everywhere, no revenue in sight!

SpicyIP is excited to bring to you yet another guest post from Sheja Ehtesham, a graduate from NALSAR University of Law currently working with Krishna & Saurashtri in Bangalore. Also my classmate, Sheja is now a self-confessed blog-a-holic and we're pleased to bring to you another post of her's in such a short span of time.
This post discusses the murky issue of revenue that is gathered from Patent Filing in India.
Patents Patents everywhere, no revenue in sight!
IP awareness has been very strongly advocated in Indian scientific communities for the past decade. A pressing need for such awareness emerged in the light of the negligible number of patents that were being filed by Indian scientists and research institutions. One of the more prominent efforts have been those spearheaded by Mashelkar, which are considered to be a tremendous success, a manifestation of which is the prominent jump in the statistics of number of patents filed by the CSIR alone. Perspectives of the scientific community appear to have undergone a dramatic change, with scientists now wanting to file patents as opposed to merely publishing their research in academic journals. Incentives were provided for the filing of such patents. The CSIR itself had a separate budget allocated for patent filings by CSIR scientists.


…And as the statistics are now flaunted with pride, as a result of these efforts, the CSIR emerged as having the highest number of PCT filings amongst all developing nations in 2002. Also, as per the CSIT website, CSIR alone had 40% share of the US patents granted to Indians in 2002. In fact, as per the most recent data available in the CSIR Annual Report of 2006-07, the Intellectual Property Management Division has filed 169 patents in India and 650 patents abroad. Thus, as the figures themselves speak, Mashelkar’s efforts are perceived to have been a large success.
However, scratching the surface a little deeper reveals this glory to be a tainted one. A massive investment has been put into the filing and maintaining of all these patents, by the CSIR. The important question to be asked at this point is, how many of these patents have actually been marketed, or commercially utilised in any way? How many of these patents serve a purpose? Several academic works point out that 60-70% of the technologies and research processes developed by the CSIR remained unutilized or could not be commercialized. Is the aim purely to have a large number of patents (CSIR as of October 2008, is said to have 3016 patents in force[3]) just so that we can boast about our statistics? Most of us are aware that the kind of investment such activity requires is colossal – and while on the one hand all this investment is being pumped in – there seem to be very feeble signs of any returns. In fact, as per statistics obtained from Mint, in 2004-05, the latest period for which data is available, CSIR filed 50 patents and generated Rs4 crore in royalties and licensing. However, it also spent Rs10 crore in filing for the new patents and in maintaining existing ones. It appears to be a rather futile exercise then, to relentlessly file patents at the cost of tax payer’s money, which are just a financial drain and are incapable of generating any financial returns. Thus, while it was crucial to promote IP awareness amongst the scientific community, the no-holds-barred way this was approached, emerges as unsatisfactory in the extreme – as what has resulted is a large number of patents requiring a correspondingly huge investment but with no returns.
It is in this backdrop that Kruttika’s recent post on incentivising the IITs gains an even greater significance. Companies such as Imperial Innovation, and Intellectual Ventures (Prashant has posted on this already in the light of them being called “Patent Trolls”) emerge as being the potential remedy to this phenomena in Indian science. In fact, several top institutions such as the IITs (for those interested, more details about the MoU between IV and IIT Bombay are available at http://www.dnaindia.com/mumbai/report_iit-b-to-encash-its-intellectual-bonds_1239735), Centre for DNA Fingerprinting and Diagnostics, IISc, and the University of Hyderabad have recognized this potential and tapped on it already. The modus operandi of these companies is that they first sign a CDA (Confidentiality Declaration Agreement) with the institute. They then perform due diligence on all the Research and Development of the institution, sifting through it to select the commercially viable R and D that has potential to actually be marketed. Once the company selects the IP, it is then their job entirely to pursue the patent, by investing their own funds, as opposed to taxpayer’s money being utilised for the same. The inventor receives milestone-linked monetary incentives at various stages, i.e. when the invention has been selected, when the patent is filed and when the patent is finally granted. What the company ordinarily gets out of this arrangement are the licensing rights of the intellectual property, and a royalty percentage is negotiated with the inventor, of all revenues earned. Anna University has also joined the bandwagon and established an in-house Centre for Intellectual Property Rights 3 years ago, that files patents for inventors and students. Till date, they have already filed about 53 patents at the Indian Patent Office at Chennai.

Companies such as these are relatively new on the Indian scene, yet are fast gaining prominence. In fact, the director of one of the top-ranking IITs recently quit in order to join Intellectual Ventures. It would seem that these companies emerge as a very attractive alternative to boost patenting in Indian science!

Tuesday, August 04, 2009

SpicyIP Tidbits: Anjali Prasad to be new DIPP JS

It's all in the family: The incoming Joint Secretary (JS) of the Department of Industrial Policy and Promotion (DIPP), is going to be Anjali Prasad, who also happens to be the wife of the outgoing JS, N N Prasad.

A comment on an earlier post on the 50 most influential people in IP led us to a blog appropriately named Babus of India from where the note was lifted.

Apologies for the slight delay in reporting this, but I was personally awaiting confirmation, which we since have. Anjali Prasad is a 1983 batch IAS officer from the Uttarakhand cadre. She was previously posted as Secretary in the Higher Education Department of the Uttaranchal administration. An economist trained at the Delhi School of Economics, she also has a WIPO diploma in IPR.

For those of you not in the know, NN Prasad will be moving to the World Intellectual Property Organisation, as the the Chef De Cabinet to the Director General of WIPO, Dr Francis Gurry. The blog had reported this a couple of months ago. The Chef de Cabinet in WIPO is the equivalent of the Principal Secretary to the Prime Minister in India.

Whether Ms Prasad's tenure will be as pioneering as Mr Prasad's will be seen in the months to come. On our part, we hope that she furthers the project of increasing transparency in Indian IP policy and institutions. And of course, we wish her all the best.

PCT v. 2.0 on the anvil?

WIPO intends to impose a "Global Patenting Regime" on the developing world, on behalf of big pharma and developed countries, if this editorial by KG Narendranath in Economic Times and this note in Pharmabiz are anything to go by. Or does it?


A Madrid System for Patents


"The WIPO plan is to institute a system similar to the one that exists for international registration of Trade Marks under the Madrid System... With the approval of Global Patenting at the General Assembly, developed nations are seeking to dilute the sovereignty of developing nations in determining patentability of applications for inventions and do way with flexibilities granted under TRIPS Agreement", Pharmabiz reports.

The proposal suggested by the USPTO, which, according to Pharmabiz, may likely be taken up in the September edition of the WIPO General Assembly, has a key feature of synthesising international and national patent application processes, leading to the "automatic grant of patents in all member states".

So, what's the problem?

At the outset this may seem as a great idea (no administrative hassles, taking "single window" application to a whole new level, etc.), there are several fundamental problems with this:
(1) it may undermine national patent laws as they exist in their nuanced variations across the world.
(2) Patent prosecution will be a whole new ball game - no scope for pre-grant opposition in the new system, and post-grant opposition would require domestic overhaul (more "assistance" from WIPO to "equip" domestic infrastructure?)

KG Narendranath reads murkier strategy into this proposal for institutional reform. In a strongly-worded edit that is full of seemingly attributed "quotations", but no sign of a source entity or document, he alleges that (and I paraphrase)
  • WIPO has changed track from its core function of capacity-building of patent offices to "breach the rank of developing country groups"
  • WIPO is seeking to "alienate India, discredit its mission at Geneva and ‘use’ Indian bureaucrats at its secretariat."
  • This is part of a larger tactic to create new barriers to the generic drugs trade (referring to the EU Customs issue) using the facade of counterfeiting.
  • Messy ACTA negotiations, and so on...

But, will WIPO really clear PCT v. 2.0?

On my part, I would hesitate to make blanket allegations against WIPO's decision-making ability.

The USPTO and a few other jurisdictions may have chosen to push their agenda, and stealthily, so might have a section of the global industry. There's no point whining: this is practical politics. However, I don't discount the ability of Indian and other developing country negotiators to ensure that institutional reform of this nature does not go through. Towards my own case, I invite you to read the documents from the latest meeting of the PCT Working Group held in May this year, which acknowledges the US proposal, along with a few others, but categorically states that the PCT system does not seek to harmonize substantive patent law. For your convenience, I reproduce some relevant text below:

[Para 5 of the Summary] "The Meeting agreed that the relevant PCT bodies should continue their work to improve the PCT. The Meeting agreed that the PCT system can and should function more effectively, within the existing legal framework of the Treaty provisions,
– to deliver results which meet the needs of applicants, Offices and third parties in all Contracting States;
– without limiting the freedom of Contracting States to prescribe, interpret and apply substantive conditions of patentability and without seeking substantive patent law harmonization or harmonization of national search and examination procedures."

A more detailed reference to this conclusion can be found in the Report of the Working Group, here:

[Para 87]
"Several delegations... raised concerns about the proposed system under which... an international application, having received a positive international report on patentability, would automatically issue as a national patent unless a national Office issued a notification of refusal within a specified period of time. Those delegations noted that such proposals would be ineffective in the absence of substantive patent law harmonization, and emphasized the sovereignty of Member States to prescribe substantive conditions of patentability."

[Para 25]:
"The Director General emphasized that the PCT was a procedural Treaty which explicitly stated in Article 27(5) that it should not “be construed as prescribing anything that would limit the freedom of each Contracting State to prescribe such substantive conditions of patentability as it desires.” Articles 27(6), 33(1) and 35(2) reinforced this message, making it clear that any international report was non-binding and was not to contain any statement on the question whether the claimed invention was or seemed to be patentable or unpatentable according to any national law. This flexibility at the national level was an important factor in the success of the Treaty that had allowed it to be adhered to by, at present, 141 Contracting States. It was explicitly stated in document PCT/WG/2/3 that the process envisaged by the International Bureau was to improve the system within that existing framework and not to address matters of substantive patent law harmonization or of a unified “international patent”.

[Para 26]:
Furthermore, the Director General noted that the “reservations” which the International Bureau considered important to address related to incompatibilities which States or Offices had notified in respect of certain procedural matters introduced during the process of PCT Reform, rather than the reservations provided for in Article 64. Nevertheless, there was room to clarify and emphasize these matters within the draft roadmap itself to make the proposed scope of the exercise fully clear.

PCTv, please

'What did India say at the meeting', is of course my next question. I suspect that may remain a mystery for the time being, unless someone can conjure up notes from the gathering! Watching the Indian Parliament on TV is terribly entertaining. Surely a TV channel for international negotiations would out-do that on the entertainment factor by several degrees? WIPO TV, anyone?

Monday, August 03, 2009

Government to introduce a whistle blower scheme in a bid to counter spurious drugs

The Union Health Minister Mr. Ghulam Nabi Azad has proposed, in Parliament, a whistle blower scheme for all those informants who volunteer with information on spurious or counterfeit drugs. According to the policy a maximum of 20% of the total cost of consignments will be payable to the informant provided that the total compensation does not breach a ceiling of Rs. 25 lakhs. Even government officials can claim rewards under this new policy. Kudos to the Government of India for coming up with this innovative scheme which is sure to create immense pressure on the substandard/counterfeit drug manufacturers. This is the latest in a string of policy initiatives by the Government, the last being the amendment to the Drugs and Cosmetic Act. This latest amendment created stringent penal provisions, with a minimum of 5 years imprisonment which can be extended to life.

The problem of fake/counterfeit/spurious drugs is beginning to create problems for the entire Indian pharmaceutical industry which has so far managed to build up an excellent reputation on account of both price and quality. The Government of India has been in the process of carrying out a study to document the actual magnitude of the problem. A recent pilot study carried out by a group of researchers, [including Dr. Roger Bates, who recent authored this article for the WSJ and Dr. Bibek Debroy (who was recently an expert witness in the mega compulsory licensing dispute at the Copyright Board)] in Chennai and Delhi came to the conclusion that whilst 5% of all drugs in Chennai were spurious, 12% of all drugs in Delhi fell in the same category. According to the study these figures indicate an improvement in the regulatory mechanisms, especially in Chennai. More importantly the Study points out that spurious drug exports are beginning to affect the image of the Indian pharmaceutical companies. African countries like Nigeria are beginning to bar imports from atleast 25 Indian pharmaceutical companies.
A related problem with the international pharmaceutical trade is that there is no uniformity in the definitions of what qualifies as counterfeit and substandard. The IMPACT negotiation which we blogged about here were shot down by the Indian Government despite Indian law providing for almost similar definitions. The devil therefore lies in the definition.

Guest Post: A critical analysis of the Indian Policy on seeds - Bane or Boon?

We're pleased to bring to you a guest post by Nirajan Man Singh & Sheja Ehtesham, both of whom will be graduating from NALSAR this weekend. Their post deals with the Seed Act, 2004 which is scheduled to be tabled in Parliament amidst severe opposition from farmer associations.

A CRITICAL ANALYSIS OF THE INDIAN POLICY ON SEEDS – BANE OR BOON?
India is predominantly an agricultural country. 31% of its GDP comes from agriculture and around 64% of its labour force is dependent on agriculture.[1] Thus any developments in the arena of agriculture warrant a very close scrutiny. Especially in the light of the widely accepted perception that seeds belong to farmers, as they are the discoverers, selectors and protectors of agricultural biodiversity.[2]

The trend that emerges is that a majority of the private investment in the area of agriculture goes to seeds other than wheat and rice. Rice and wheat are domains wherein the investment is mainly from public research institutions funded by the Government, which naturally, is not sufficient. The merits of this policy are questionable and it has often been criticized as being a key factor in reinforcing poverty in a majority of the population. Consequentially, it has emerged as the need of the hour to attract further investment in rice and wheat. Accordingly, the Government decided to permit private participation in this field. They further endeavored to ensure that there were enough safeguards introduced in new Seed Bill and the Protection of Plant Varieties and Farmers’ Rights Act (i.e. PPV & FR Act) to reduce the scope of any misuse.

The introduction of foreign and domestic private participation would inevitably increase the investment in the area of food and agriculture. It will bring new varieties of seeds to the farmer with higher productivity. This was, perhaps, the main objective behind allowing for an inevitable, yet limited monopoly to private players. It seems reflective of the Government’s consciousness of the fact that its investments alone will not suffice to provide for food security to the country. Private participation is the need of the hour. Furthermore, the disadvantages to bringing in the private players are substantially counterbalanced, considering there is nothing in the existing legislation which provides that seed saving is a crime.

BT COTTON: FARMER STITCH THEIR OWN SHROUDS

In 1996, an insect resistant Bt cotton was discovered by introducing Cry1Ac gene from a soil borne bacteria, Bacillus Thuringiensis (BT) and was commercialized in USA and subsequently in other countries. Those varieties of Bt cotton have reportedly failed in large parts of Madhya Pradesh causing serious losses to farmers. Reports of the failure of Bt cotton have been coming in steadily after the harvest of the first crop of 2002- 2003. Gene Campaign’s study of the first Bt cotton harvest in Andhra Pradesh and Maharashtra had shown that 60% of the farmers who cultivated Bt cotton in these regions had suffered such massive losses that they were unable to even recover their investment.[3]

As per the Andhra Pradesh Government Report of the Bt cotton failure, the state has banned the sale of such varieties of Bt cotton, due to the large scale losses incurred by farmers. The cause of such a colossal failure of Bt Cotton in India was that India’s Bt Cotton technology was faulty and inadequate to protect the cotton crops, where the major pest is the bollworm. Bt cotton hybrids being produced in India were found to be unstable and unpredictable and not very effective against the bollworm, as the variety being used here was created for the US, to protect America’s cotton crops against its major pest, which is the tobacco budworm, not the bollworm.[4]

The poor performance of Bt cotton in India can also be attributed to the fact that in India, Bt cotton seeds were produced as hybrids, not the true varieties. It could possibly have been a wiser choice if the government undertook the decision that only true breeding varieties of Bt cotton would be permitted in India, not only because they perform better but also because they would be a cheaper option for farmers who could save seeds for the next harvest.[5]

The Navbharat Bt seed was another variety selling cheap at Rs 100 per bag, since it was illegal – similar to selling on the black market, at a lower cost. The tragedy began unfolding inGujarat where over 10,000 acres of Bt cotton were planted illegally. The Genetic Engineering Approval Committee (GEAC) of the Union Ministry of Environment and Forests, whose permission is required for cultivation of any GM crop, ordered the destruction of this illegal Bt cotton that was still standing on the field. This decision led to numerous farmers committing suicide.

Despite the widespread failure of such Bt cotton varieties neither the Genetic Engineering Approval Committee (GEAC) nor the Ministry of Agriculture, have so far moved to take action against the offending company. The company contended that the failure was attributable solely to agronomic conditions like shortage of water or heavy rain, hence it was reported only from a few pockets, and not the whole country.

SEED MANAGEMENT SYSTEM IN INDIA: WHERE DOES IT STAND?

The major change in the patent regime achieved through the second amendment is not in the area of drugs as is commonly believed, but in the area of seeds and plants, especially genetically engineered seeds. Methods of agriculture and plants were initially excluded from patentability under the Indian patent act to ensure that seed, the first link in the food chain, was held as a common property resource in the public domain and farmer’s inalienable right to save, exchange and improve seed was not infringed upon.

Prior to globalisation, peasants never felt threatened, as there were no barriers to exchange, distribute or multiply the seeds.[6] It was treated largely as an accepted cultural practice inherent in the peasant economy. Today, however, the multinational seed industries are steadily encroaching into this area.

There are certain safeguards in the PPV & FR Act[7] to prevent the interests of farmers. The Farmers are entitled to save, use, sow, re-sow, exchange, share or sell their farm produce including seed of a variety protected under the Act. The breeder while selling any propagating material of a variety registered under the Act shall disclose to the farmer the expected performance under given conditions, and on failure to provide such performance the farmer can claim compensation. Section 39 of the Act protects innocent infringement by a farmer. Also, Section 41-42 provide for a community to have a right in benefit sharing if that community has contributed to the evolution of the variety. There is also a provision for compulsory licenses if a reasonable requirement of the public for the seed is not satisfied.

Since time immemorial, Indian peasants have produced their own seeds locally. In a country where 70% people depend on agriculture for survival, 75% of the seeds used for agriculture are produced by the peasants themselves.[8] Thus, it is evident that farmers have always enjoyed a wide ambit of rights with regards to agricultural seeds. With the coming of the Seeds Bill, 2004, the scope of these rights is severely curtailed. The Bill fails to regulate and hold Indian private seed companies and MNCs liable, which has had devastating consequences for farmers. The loss of more than Rs 1,000 crores incurred by peasants in Bihar recently due to the failure of maize seeds, the recurring failure of Bt cotton seeds, and the ensuing suicides by hundreds of farmers in Andhra Pradesh are all manifestations of the failure of those companies in delivering quality seeds to Indian farmers.[9]

It has been argued by policy makers in defense of the Act, that there is no provision in the Seed Bill 2004 that has the potential to make peasants completely dependant on the seed market, especially in the light of Section 43 gives farmer the right to save, use , exchange, share or sell his farm produce without registration.[10] Yet, oddly enough, the very same Bill also stipulates that no seed of any kind or variety shall, for the purpose of sowing or planting by any person, be sold unless such seed is registered.[11] What emerges is a set of complex and starkly conflicting laws at a very fundamental level. Furthermore, if a farmer sells any seed which does not conform to the standards of physical purity, he shall, on conviction pay a fine of up to Rs. 25,000.[12] This means that farmers involved in the traditional practice of seed sale and barter across their farm fence can be charged under the new Bill. The farmer attracts penal action, if he misbrands any seed, supplies any spurious seed, sells any non-registered seeds, and if convicted he is punished with an imprisonment for a term which may extend to six months or with a fine of upto Rs. 50,000 or with both.[13]

If the farmer were to be denied the right to sell, it would not only result in a substantial loss of income for him but far more importantly, such a step would displace the farming community as the country's major seed provider. Control over seed production is central to food security, which is in the forefront of national security.

Furthermore, there is the liability to be searched by the Seed Inspector who has been given powers to break open and enter houses and search if he is of the opinion that the Seed Act is being violated. [14] It would almost seem that the idea is to make the whole process so bureaucratic that the farmer is rendered uncompetitive in the market. It is impractical to expect any farmer to expend the energy, time and money to go to a committee or an institution to ascertain the quality of his seed, get a certificate of approval and then sell, save or share it. This will only lead to widespread corruption and farmers will have to bear the brunt.

Another case in point is the issue of seed certification. It is pertinent to note that such seed certification is not mandatory. It is provided for in the new Bill, for those who desire to have seed certified. Under the existing Act (Seed Act, 1968) only central or state seed laboratories can provide seed certificates. But under the new Bill, accredited individuals or institutions will also be able to provide such certificates. This will allow self-certification. Any seed company may establish an institution and certify its own seeds. The scope of abuse is unbridled.

Also, in case of crop failure, apart from the provision in Seed Bill there is a provision in PPV & FR Act which says that the breeder while selling any propagating material of a variety registered under the Act shall disclose to the farmer the expected performance under given conditions, and on failure to provide such performance the farmer can claim compensation. A valid concern here is compensation to farmers when the agronomic performance claimed by the seed provider fails to perform.[15] The proposal asks the farmer to claim it through consumer courts, knowing the tedious processes of consumer courts and their inaccessibility to rural masses, one reaches the conclusion that it is a provision that will deter the farmer from claiming the compensation.

The Seed Act seems to be designed to impinge into the free economy of farmers seed varieties. Once farmers’ seed supply is destroyed through compulsory registration by making it illegal to plant unlicensed varieties, farmers are pushed into dependency on the corporate monopoly of patented seed. The Seed Act is therefore the handmaiden of the Patent Amendment Acts which have introduced patents on seed.
As mentioned in part 1 the importance of agriculture in India is interminable. Though 3/4th of the land is under food crops, the country could not be self sufficient. Every year 3 to 4 million tonnes of food grains have to be imported. The inadequate production of foodstuff and the consequent high prices constitute the main problems in the Indian Economy. But even when there is acute shortage of food grains, population is mounting by 10 – 15 million a year.
In the first set, the paper covered a wide range of topics – from the basic consideration and issues to the more specific technical concerns of structural measures for seed usage in India. There is more dialogue in the second set on the administrative issues of seeds with reference to TRIPS, UPOV, CBD.
PATENTS SYSTEM FOR LIFE FORMS AND PROCESSES – SUITABILITY IN QUESTION

One of the key objectives, of ensuring the availability of seeds at affordable prices, was fulfilled by the Patent Act 1970, as it barred seeds from being patented. It allowed India to specialize in the production of cheap seeds as well as export it to other countries. The move to product patent, however, makes such production and commerce illegal. As a consequence, the price of newly patented seeds is set to rise sharply in the region, imposing a significant social and economic cost on the country. Nonetheless, as developed nations have argued, higher prices are necessary to ensure the delivery of new and better seeds in the future. The question that emerges is, at what cost?
Patents have been filed on indigenous plants which have been used for generations by the local people, without their knowledge or consent. The locals then find that the only way to use their age-old knowledge is to buy them back from the big corporations. In Brazil, which has some of the richest biodiversity in the world, large multinational corporations have already patented more than half the known plant species.[16]
Indian agriculture has had a consistent growth over the past three decade due to favourable government policies and limited competition from overseas. However, it seems that the nation is being forced to reassess its long-term strategies and business models as India opens its markets to global trade. However, what is to be kept in mind, especially with respect to an agricultural economy like India, is that inaccessibility or unavailability of seeds due to such “Seed Policy” can have devastating consequences on a majority of the population.
The Supreme Court of India recognized the enforceability of right to health within the scope of Article 21 of the Indian Constitution[17] . Furthermore, Article 15(1) (b) of the ICESCR recognizes the “right of everyone to enjoy the benefits of scientific progress and its applications.” The Supreme Court has often interpreted fundamental rights in consonance with international treaties. Hence, the implementation of product patents should not result in the complete denial of rights guaranteed under the Constitution of India and the ICESCR. According to Section 2 (d) & (f) of Protection of Human Rights Act, 1993 rights under the ICESCR are the rights that the National Human Rights Commission (NHRC) has to protect.[18]
The TRIPS agreement requires all member countries to introduce a sui generis[19]system for the protection of new plant varieties.[20] India had no choice but to carry out these changes under the agreement. Such changes will undoubtedly have a huge impact on public research activity, private research, foreign direct investment and technology transfer in the seeds sector. However, the necessity of a complete overhaul of a system that has been in place for years is questionable, as in the sui generis system (i.e. PPV & FR Act) there are already adequate safeguards for the protection of public and private research activity.[21]
The Union for the Protection of New Varieties of Plants (UPOV) is an internationally harmonised sui generis system for this purpose. It has several members today, mostly developed nations. India has submitted the PPV & FR Act for examination to the UPOV to determine compliance with the UPOV Convention, and while it is not a member yet, it is likely to become one soon.[22] The UPOV establishes a very strong system to protect the rights of the plant breeders; also, the breeder can apply for rights in any other member country. With such a rigid support structure for plant breeders, the desirability of India becoming a member of the UPOV seems controversial and questionable in the extreme.
The Convention on Biological Diversity, 1994, is an alternate international convention that came into force in 1994. The CBD lays emphasis on national sovereignty over the genetic resources of a country, and the protection and the promotion of the rights of local and indigenous communities. Thus, there seems to be a conflict between the TRIPS and CBD, especially with respect to patenting of life forms. Several nations opine that the TRIPS should be amended to be in conformity with the CBD, i.e. with a greater emphasis on protection of the rights of indigenous and local communities against possible negative impacts of bio-patenting.[23]
Article 27 of the TRIPS agreement provides that a legal infrastructure to Patent Life forms (including plant) is a compulsory obligation, provided that plant varieties are protected by effective sui generis system. However, the authors propose that patents on genetic resources for food and agriculture should not be allowed under the TRIPS agreement, as it undermines the right to food as recognised in Article 25 of the Universal Declaration on Human Rights, and reaffirmed in the International Covenant on Economic, Social and Cultural Rights (Article 11) and the Convention on the Rights of the Child (Articles 24, 27). There is an inherent contradiction between human rights and the TRIPS agreement.[24] This argument is further reinforced when the UN Sub-Commission for the Protection and Promotion of Human Rights passed a resolution stating that the TRIPS Agreement does potentially infringe on poor people’s right, especially their access to seeds and pharmaceutical drugs. Not only can the patenting of food and seeds lead directly as well as indirectly to a denial of the right to food, but in granting a two decade long monopoly on ‘inventions’ relating to food and farming crops, particularly staples, we are sacrificing the free and public exchange of technology that may benefit the poorer sections of society. Thus, in the light of the dependence of a large segment of society on seeds, neither the seeds nor developments of these seeds should be subject to private monopoly.

NO PLACE FOR MONOPOLIES IN SEED POLICY
Somewhere in the world, a man, woman or child dies of hunger every 3.6 seconds. In this context, more than 1.4 billion people in developing countries depend for their survival on crops they grow from seeds saved from their last harvest.[25]
The seeds policy has no mechanism to limit monopolies in agriculture. The inevitable consequences of displacement, hunger and famine will follow such a regime that is monopolistic over food production and consumption, through their control ownership over seed, which is the primary link in the food chain.
Such policies can lead to and reinforce already extant poverty at a primary level, i.e. an inability to command enough income to buy the bare necessities of life.[26] Accessibility and affordability of seeds is a major concern in India today, and it is time that law makers prioritise, rather than get influenced by foreign seeds policies which are not suitable for Indian agricultural fabric.

[1] Uma Kapadia, “Understanding the Problem of Indian Economy”, 4th ed. 2003, p. 477
[2] R. Radhakrishna and Alakh N. Sharma, “ Empowering Rural Labour In India: Market, State and Mobilisation”, 1st ed. 1998, p. 44

[3] Suman Sahai, “The Failure Of BT Cotton”, www.genecampaign.org last accessed on April 2nd 2008.
[4] Suman Sahai, “ Performance of BT Cotton India: Data From The First Commercial Crop”, Economic & Political weekly, July 26-1 Aug2003, Vol-XXXVIII No.30 pp 3139-3141.
[5] Suman Sahai and Shakeelur Rehman, “ Bt Cotton: field swamped with illegal variants”, www.epw.org.in last visited on 4th April, 2008
[6] G.S.Bhalla, “Globalisation and agricultural policy in India”, p.122.
[7] The Protection of Plant Varieties of Farmers Rights Rules, 2003.
[8] Dr. Gupta, “Seeds Bill 2004: A Blueprint to Murder of Indigenous Seeds”, www.peoplesmarch.com last visited on 14th April, 2008.
[9] P Sainath, “when farmers die”, http://www.indiatogether.org last visited on 9th April 2008.
[10] The Seeds Bill, 2004.
[11] Chapter 3, clause 13.(1) of The seeds bill, 2004 reads No seed of any kind or variety shall, for the purpose of sowing or planting by any person, be sold unless such seed is registered under sub-section (2) by the Registration Sub-Committee in such manner as may be prescribed.
[12] Chapter 8, Clause 38 of the seeds bill, 2004 imposes punishment on any person who contravenes with the provisions of the Act. The Clause 38 (2) states If any person sells any seed which does not conform to the standards of physical purity, germination or health or does not maintain any records required to be maintained under this Act or the rules made there under he shall, on conviction, be punishable with fine which shall not be less than five thousand rupees but which may extend to twenty- five thousand rupees.
[13] Chapter 8 Clause 38(3) of the seeds bill, 2004 says If any person furnishes any false information relating to the standards of genetic purity, misbrands any seed or supplies any spurious seed or spurious transgenic variety, sells any non-registered seeds he shall, on conviction be punishable with imprisonment for a term which may extend to six months or with fine which may extend to fifty thousand rupees or with both.
[14] Chapter 6 Clause 35 of the Seeds Bill, 2004 addresses that The Seed Inspector may take samples of any seed from any person selling such seed or conveying, delivering or preparing to deliver such seed to a purchaser or a consignee. He can enter and search, at all reasonable times, with such assistance, if any, as he considers necessary, any place in which he has reason to believe that an offence under this. The power to break-open the door of any premises where any such seed may be kept for sale, when the owner or any other person in occupation of the premises, if he is present therein, refuses to open the door on being called upon to do so.
[15] CHAPTER 3 Clause 20 of the Seeds Bill, 2004 Where the seed of any registered kind or variety is sold to a farmer, the producer, distributor or vendor, as the case may be, shall disclose the expected performance of such kind or variety to the farmer under given conditions, and if, such registered seed fails to provide the expected performance under such given conditions, the farmer may claim compensation from the producer, distributor or vendor under the Consumer Protection Act, 1986.


[16] David Hathaway, “Brazil about to Patent Life?”, www.grain.org last accessed on 12th April, 2008.
[17] Vincent Panikurlangara v Union of India,1987 (2) SCC 165.
[18] Human Right Act, 1993, http://nhrc.nic.in/ last visited 12th April, 2008.
[19] Black’s Law Dictionary, sui generis : the only one of its kind.
[20] Article 27.3 (b) of TRIPS states: “Parties may exclude from patentability plants and animals other than micro-organisms, and essentially biological processes for the production of plants or animals other than non-biological and microbiological processes. However, parties shall provide for the protection of plant varieties either by patents or by an effective sui generis system or by any combination thereof. This provision shall be reviewed four years after the entry into force of the Agreement establishing the WTO."
[21] S. 30, PPV & FR Act.
[22] http://www.managingip.com/Article.aspx?ArticleID=1941365
[23] Ibid
[24] Human Rights and Human Development, The latest Human Development Report 2000 of the UNDP, www.Undp.org last visited on 15th April, 2008
[25] http://www.devp.org/pdf/seedpatents1.pdf, Why Seed Patents Threaten Food Supply For The World’s Poor.
[26] Paul Streeten, “ poverty concepts and measurement”,Thinking about development, 1995.

SpicyIP Tidbit: Glasgow Wants Protection for Chicken Tikka Masala

After calls for a GI for Birmingham’s Balti dishes on which Sumathi had blogged early last month, it is now chicken tikka masala’s turn.

According to the Financial Times, an MP from UK’s Labour Party, Mohammed Sarwar, has asked for a European Union protection in the form of a Protected Designation of Origin (PDO) to be granted to the dish as a “Glasgow Recipe”.

He claims the dish was created in Glasgow’s Shish Mahal restaurant in the 1970s (Wikipedia too gives the same year).

Not everyone seems to share Mr.Sarwar’s enthusiasm since there are apparently 48 varieties of this dish (according to a 1998 survey by Real Curry Restaurant Guide), all of which have nothing in common but for the chicken.

Interestingly, in a letter to the FT, the former editor of the Real Curry Restaurant Guide under whose editorship the survey was conducted wrote that the dish was claimed to have been invented way back in the 1950s in London putting in doubt its true origins.

Whatever be the case, this is one spicy affair I would like to watch out for.

For those interested in reading more about curries and dishes, here’s a link to an interesting news item on a competition for curry and balti restaurants.


Guest Post: Is OSHO a Trademark - Osho Friends to the Rescue

We bring you a guest post on controversial case of the Osho trademark, as decided by the Trademark Trial and Appellate Board (TTAB) in the US. You will recall our previous posts on the frequently coinciding paths of the sacred and the profane in IP, which you can sample here, here and here. Today's post is in continuation of the same, and draws attention to the detailed discussion by the TTAB on whether or not OSHO could be regarded as generic, and related matters.(Image: Wikipedia)

(Interestingly, as an aside, the website of Osho Friends International has a banner proclaiming "OSHO Everybody's Birthright - Nobody's Copyright", perhaps in response to the various matters that have gone litigious in the recent past.)


Our guest blogger for this post is Abhishek Malhotra, an IP advocate admitted to practice in India and California, with nearly ten years of experience,
based in Delhi. Abhishek's expertise ranges across IP issues, as well as on information technology, employment and competition issues. He regularly advises clients across industry sectors on the creation, maintenance, management and enforcement of IP rights. He has also provided inputs to the Government of India on the Copyright Act, and spoken at conferences held by the International Trademark Association and the World Intellectual Property Organisation. He is also a regular contributor on the Indian position for various issues pertaining to the music industry for the annual legal publication of the International Association of Entertainment Lawyers.

The decision discussed below is available as a download here. It will be of interest for readers to know, as Abhishek points out in his note, that this TTAB decision was appealed against by the Osho International Foundation, but later withdrawn, thereby making the order of the TTAB final. The post follows.


Is OSHO a trademark - Osho Friends to the
Rescue


The Trademark Trial and Appellate Board, USA (TTAB), has, after a long and interesting trial, answered the question with an emphatic NO.


This decision is music to the ears of Osho sanyasins who have been using Osho’s name to identify their activities
for the last 20 years and who have, of late, been constantly threatened with legal action by Osho International Foundation (OIF) based on OIF’s claimed trademark rights and copyrights in and to Osho and content attributed to him.

More Good news. The appeal filed by OIF has been withdrawn by OIF and the Court of Appeals for the Federal Circuit has passed an order making the order of the TTAB final.

The applications and registrations for OSHO and variations of OSHO were discovered by Osho World Foundation (Osho World), the founder members of Osho Friends International (OFI) when OIF filed a case against Osho World for transfer of domain name, Oshoworld in 2000. The case was based on these registrations and applications in USA. Osho World won that case and followed up on the victory with filing cases for cancellation or registered trademarks and opposition to the registration of pending applications for OSHO and its variations.

The main arguments were:
  1. That the word OSHO was generic, i.e., it was required to be used for identifying all activities and teachings of OSHO.
  2. That OSHO was primarily used to describe all such activities and teachings.
  3. That OIF played a fraud on the US Patents and Trademark Office (USPTO) by stating that no one except OIF was entitled to use OSHO even though OIF knew of the various centers using OSHO in their names and in connection with their activities.
The TTAB, after hearing both parties and looking to the evidence filed and testimonies of all persons concerned, concluded that OSHO was generic and descriptive in respect of the activities and teachings of OSHO and hence the registered OSHO trademarks are to be cancelled and the applications for OSHO are to be rejected. As the TTAB ruled in favour of OFI on the first two arguments, it did not give a determination on the third argument of fraud. Some of the important statements of the TTAB in its decision, which include important findings of fact, are quoted below:

Osho urged and authorized his followers to spread his teachings as broadly as possible, throughout the world. To this end, his followers transcribed and recorded his discourses and shared them with others during Osho’s lifetime. In addition, Osho’s followers opened meditation centers and camps in different parts of the world, offering several of his meditation techniques. These followers have created and offer their variations of music, cultural and celebratory events, education and therapeutic courses, workshops and retreats based upon Osho’s ideas. Some of these followers and their centers have offered and continue to offer publications, recordings and newsletters relating to their activities and Osho’s ideas. Such centers have also begun operating internet websites relating to the same subjects. These centers operate independently and separately from one another, without coordination by any single source or hierarchy. Osho gave each center a name as a gift and a certificate bearing such name. However, Osho neither controlled nor created a hierarchy to control or supervise these centers. Nonetheless, in 1989, upon adoption of his name, Osho requested that the centers use Osho in their names so people would recognize them as meditation centers based upon his teachings and ideas. Most centers immediately complied with this request.

“…there is no evidence of record that the individual known as Osho ever used OSHO as a trademark. Indeed, the parties agree that Osho never owned or used OSHO as a mark. Thus, the record in this case supports a finding that Osho himself neither claimed nor used OSHO as a trademark. The record further supports a finding that Osho gave permission to his followers to individually open centers utilizing his name to spread his teachings throughout the world. In addition, the record supports a finding that upon his adoption of the name, Osho requested that such centers utilize OSHO at the beginning of their titles so they would be recognized as “Osho meditation centers.” Finally, the record supports a finding that Osho never withdrew his permission for such centers to refer to themselves using his name.

“…
defendant (OIF) cannot appropriate the term OSHO to identify the source of its goods and services related to such teachings.

Because the evidence of record shows that consumers identify the term OSHO with a series of meditative and religious teachings, defendant (OIF) cannot monopolize such teachings by asserting trademark rights in the generic term used to identify them.

In this case, testimony and evidence of record establishes that Osho himself requested that his followers change the names of their centers to include OSHO so that they would be recognized as “Osho centers.” Further testimony and evidence establishes that the term OSHO is necessary to describe the meditations, practices and beliefs that form the core of the OSHO meditative and religious movement. As such, the term OSHO must be freely available for the practitioners and followers of the mystic Osho to be able to identify their activities based upon his teachings. Based upon the foregoing, we find the term OSHO is generic for the meditations devised by the mystic Osho and the meditative and religious movement arising therefrom. As a result, defendant (OIF) cannot foreclose others from utilizing the term OSHO to describe their own goods and services based upon such meditations and movements. Accordingly, we grant plaintiff’s (OFI) petition to cancel as to those marks consisting in whole of the term OSHO.

What does this mean for OSHO sanyasins?

This decision means that OIF cannot claim a monopoly in the USA on use of the word OSHO in relation to Osho’s teachings and activities and cannot use these registrations and applications to threaten anyone who is using OSHO in relation to Osho’s teachings and activities or as names of their centers/web addresses.

While OIF may try to rely upon registrations of OSHO and its variations in other countries, these would now become vulnerable and perhaps open to challenge based on the detailed finding given by the TTAB.

Saturday, August 01, 2009

The Fate of the Rosiglitazone Patents: Far From Rosy?

Recently, a colleague of mine asserted that till date, GSK had obtained only one pharmaceutical product patent in India! Given that GSK has the largest sales in India (of all the MNC's operating within India) and have introduced most of their global products in India as well, this figure seems a tad too difficult to believe. Anyone in the know from amongst our readers?

And with this puzzling statistic, which if true, could raise some very interesting questions about the Indian patent regime, let us move on to GSK's famous Rosiglitazone patent applications, one of which made it to the Supreme Court of India and featured in earlier blog posts. The fate of these applications and what they mean for GSK and its generic competitors is examined in the below note by Lakshmikant Goenka of Dolcera, a leading patent intelligence firm.

Case background


Avandia is the popular drug name marketed by GSK had strong sales of 2.3 billion USD in 2007 till reports of its cardiovascular risks came out in the market place (forcing lots of physicians to change prescriptions to their patients, though the data was proclaimed as inconclusive by FDA).

Avandia finds strong applications for glycemic control or in others words for diabetes type II treatment. Its active ingredient is a compound called Rosiglitazone, and a variant of this chemical compound was patented by GSK with expiry in 2005 (US5741803).

GSK Indian strategy


Per change in the Indian patent act in 2005, GSK filed a patent for the same active ingredient as disclosed in US 5002953 as an Indian patent 00295/DELNP/2003 trying to claim the ethanesulfonate salt of the active ingredient. This patent was subsequently rejected by the India Patent office citing no evidence of the complex showing substantially different clinical efficacy than the available pharmaceutical version of Rosiglitazone.

However, it is interesting to note that GSK has not given up. It has at least three more pending application before the IPO for the same compound Rosiglitazone and we will have to see how the IPO deals with that. These applications are:-

a) IN3546/DELNP/2004 in which GSK has tried to patent a cyclodextrin complex of rosiglitazone and

b) IN4030/DELNP/2005 in which GSK has tried to patent the process for manufacture of a rosiglitazone polymorph (the maleic ester form as patented in US7358366)

c) IN6569/DELNP/2007 in which GSK has tried to patent a novel method of delivering rosiglitazone (enmeshed in nanofibres)

To counter this threat, Cadila and Dr. Reddys have also filed process patents for manufacture of amorphous Rosiglitazone maleate.

Only time will tell, who will win the Rosiglitazone turf war in India.

Sources:

FDA Orange book
Indian Patent office
US Patent Office
Economic times

Note: More such analysis and IP analytics information can be found in the Dolcera Blogs